Under the agreement, BioSeek’s BioMAP Systems will be used to help further evaluate selected compounds associated with several of Lexicon’s drug discovery programs.
BioMAP Systems are a series of human primary cell-based assay systems designed to replicate the intricate cell and pathway interactions present in human disease biology.
Michael Venuti, CEO of BioSeek, said: By providing predictive preclinical human data on the pharmacological properties of Lexicon’s compounds, the BioMAP platform can help to discern the relevant physiologic pathway impacted by the compounds and identify appropriate cellular assays for their further optimization.